Skip to content
Beacon

GNMXCorgi Genomics & Precision Medicine ETF

Grow my moneyNewRanked #1,477 of 2,950 in this goal

Seeks capital appreciation.

By Corgi Funds · Launched 2026

Annual Cost

0.35%

#1,651 of 5,606 · low cost

Fund Size

$1M

#5,446 of 5,606 · small

Return (1Y)Goal

-3.2%

Track Record

1 month

#5,469 of 5,606 · young

Performance

Total-return NAV · USD
Growth of $10,000
$12,132+21.3%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

Global

Strategy

Active selection

Sector

Health care

Focus

Biotech & Genomics

What it actually holds

By weight

Concentration

Top 10 holdings = 43.2% of fundmoderately concentrated

Thermo Fisher Scientific IncTMO
8.8%
Vertex Pharmaceuticals IncVRTX
7.0%
Alnylam Pharmaceuticals IncALNY
4.5%
Illumina IncILMN
4.0%
Guardant Health IncGH
3.7%
Revolution Medicines Inc Ordinary SharesRVMD
3.6%
Incyte CorpINCY
3.0%
Genmab AS ADRGMAB
3.0%
Moderna IncMRNA
2.9%
Ionis Pharmaceuticals IncIONS
2.7%

Asset allocation

Stocks
98.6%
Cash
1.4%

By sector

Healthcare
100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
97.1%High

Year-on-year price swings

Max drawdown
-99.3%Severe

Worst peak-to-trough loss

Sharpe (3Y)
-0.20Below average
Sortino (3Y)
-0.28Moderate downside risk

Listing

Exchange
Cboe BZX

Full fund details

Objective
Seeks capital appreciation.
Strategy
Actively manages a portfolio primarily invested in companies materially involved in genomics and precision medicine technologies. Invests at least 80% of net assets in equity securities of U.S. and foreign companies across all market capitalizations. Focuses on companies engaged in gene sequencing, bioinformatics, molecular diagnostics, and targeted therapies. Employs bottom-up security selection combining fundamental analysis with thematic and quantitative screening. May invest in illiquid investments and other investment companies for exposure.
Inception date
May 5, 2026
Fund family
Corgi Funds

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Thematic
Warning

These usually launch after the gains are gone

A theme gets packaged into a fund after it has already run. Over the past 15 years, fewer than one in 10 thematic funds beat a broad global index, and more than three-quarters closed down entirely. The pitch always sounds good. The returns rarely follow.

Sources: Morningstar, 'Global Thematic Funds Landscape' (2022)

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've looked at GNMX. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.

See other funds for this goal

Data updated on 2026-06-29